Evidence map›Paper›PMID 40926686›Full record

ArticleChemical biology & drug design2025

Rationally Designed InhA Inhibitors: A Comparative Anti-Tubercular Activity Study of Sulfonate Esters of Isoniazid Hydrazones and Their Structurally Flexible Benzyl Analogues.

Mukanda Gedeon Kadima, Sahil Mishra, Gobind Kumar, Pule Seboletswe, Françoise Roquet-Banères, Maëlle Foubert, Laurent Kremer, Rajshekhar Karpoormath, Parvesh Singh

Abstract read
In one paragraph

Article in Chemical biology & drug design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mukanda Gedeon KadimaDiscipline of Pharmaceutical Sciences, Westville Campus, University of KwaZulu-Natal, Durban, South Africa.ORCID https://orcid.org/0000-0003-0202-2230
Sahil MishraSchool of Chemistry and Physics, University of KwaZulu-Natal, Durban, South Africa.
Gobind KumarSchool of Chemistry and Physics, University of KwaZulu-Natal, Durban, South Africa.
Pule SeboletsweSchool of Chemistry and Physics, University of KwaZulu-Natal, Durban, South Africa.
Françoise Roquet-BanèresCentre National de la Recherche Scientifique UMR 9004, Institut de Recherche en Infectiologie de Montpellier (IRIM), Université de Montpellier, Montpellier, France.
Maëlle FoubertCentre National de la Recherche Scientifique UMR 9004, Institut de Recherche en Infectiologie de Montpellier (IRIM), Université de Montpellier, Montpellier, France.
Laurent KremerCentre National de la Recherche Scientifique UMR 9004, Institut de Recherche en Infectiologie de Montpellier (IRIM), Université de Montpellier, Montpellier, France.
Rajshekhar KarpoormathDiscipline of Pharmaceutical Sciences, Westville Campus, University of KwaZulu-Natal, Durban, South Africa.ORCID https://orcid.org/0000-0002-1247-5754
Parvesh SinghSchool of Chemistry and Physics, University of KwaZulu-Natal, Durban, South Africa.ORCID https://orcid.org/0000-0001-6742-6389

Funding

Association Grégory Lemarchal Equipe FRM EQU202103012588Association Vaincre la Mucoviscidose RF20230503223National Research Foundation PMDS230505102841National Research Foundation SRUG2204092857
6 · The paper itself

Abstract

Molecular hybridization of isoniazid with hydrophobic aromatic moieties represents a promising strategy for the development of novel anti-tubercular therapeutics. In this study, a series of hybrid molecules (5a-i) was synthesized by linking isoniazid with aromatic sulfonate esters via a hydrazone bridge. Molecular docking studies revealed that these compounds interact effectively with the catalytic triad of the InhA enzyme (Y158, F149, and K165), suggesting their potential as InhA inhibitors. To enhance molecular flexibility and improve binding interactions with both NADH and the catalytic residues, a second generation of derivatives (8a-k) was designed and synthesized. All synthesized compounds were structurally characterized using spectroscopic techniques, including nuclear magnetic resonance (NMR), Fourier transform infrared spectroscopy (IR), and high-resolution mass spectrometry. As anticipated, these new compounds exhibited enhanced anti-tubercular activity compared to their precursors. Notably, compound 8b demonstrated significant potency with an MIC of 0.078 μg/mL, approximately twofold more active than its precursor 5b (MIC = 0.156 μg/mL) against Mycobacterium tuberculosis (Mtb). However, both generations of compounds (e.g., 5a, 5b, 8a, 8b, 8c, and 8 k) lost activity against INH-resistant Mtb strains harboring katG mutations. Importantly, no cytotoxicity was observed for these compounds in THP-1 human monocytic cells at a concentration of 10 μg/mL. The structural integrity of the lead compound 8b was confirmed via

Indexed as

Antitubercular AgentsBacterial ProteinsHydrazonesIsoniazidOxidoreductasesDrug DesignEstersHumansMicrobial Sensitivity TestsMolecular Docking SimulationMycobacterium tuberculosisStructure-Activity RelationshipAntitubercular AgentsBacterial ProteinsEstersHydrazonesInhA protein, MycobacteriumIsoniazidOxidoreductasesADME/Tflexibilityhydrazoneisoniazidmolecular dockingmolecular hybridsMycobacterium tuberculosisrigidity

Identifiers

PMID40926686
PMCPMC12421295

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.